• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Lack of Partnering Hindering APAC Pharma Innovation


Pharmaceutical Executive

Clarivate Analytics, a global company providing insights and analytics, announced that it published a new report called “Pharmaceutical innovation in the APAC region: A quantitative company ranking and future outlook.”

The report provides insights on which countries/regions in the Asia-Pacific region are most conducive to innovation, which companies lead the way today or are poised to lead tomorrow, and how a company’s innovation profile affects its success. Report findings show, while exhibiting strong drug development capability, greater early stage partnering and increased academic collaboration are needed for companies in the APAC region to expand their global footprint.

Of the 929 companies studied across 14 countries/regions in APAC, there are 5,893 drugs in active development and 1,549 that have been launched. Japan, due to its market maturity, has the highest innovation score across all three innovation indices, with China and South Korea positioned as strong contenders for the most innovative country. Japan, China and Korea alone account for 80% of drugs in active development.

View or download the full report here.


Related Videos
Related Content